Company news

Qiagen N.V. news in 2025

Qiagen N.V.'s news releases, calls and decks from 2025, newest first.

View company

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

December 18, 2025

QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

November 10, 2025

QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

November 4, 2025

QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

November 4, 2025

QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025

October 30, 2025

QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing

October 28, 2025

QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

October 13, 2025

QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

September 10, 2025

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

September 2, 2025

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

August 28, 2025

QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds

August 28, 2025

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds

August 28, 2025

QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability

August 5, 2025

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels

July 22, 2025

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast

July 8, 2025

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

June 26, 2025

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

June 18, 2025

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

June 15, 2025

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

June 2, 2025

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

May 22, 2025

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

May 12, 2025

QIAGEN announces plans for transition in leadership of Supervisory Board

May 7, 2025

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

May 7, 2025

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

May 7, 2025

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

April 29, 2025

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

April 22, 2025

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

April 15, 2025

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

April 8, 2025

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

April 6, 2025

QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

April 1, 2025

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

March 31, 2025

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

March 6, 2025

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

March 3, 2025

Calls in 2025

Decks in 2025